Recent Announcements

PhotoPharmics, the leader in specialized phototherapy for neurodegenerative diseases, today announced the successful enrollment of its first 25 patients into the Celeste Light for PD Trial. This groundbreaking trial represents a significant advancement in Parkinson’s disease (PD) treatment, where motor treatments become less effective over time, and no FDA approved treatments exist for many debilitating non-motor symptoms.

“People with Parkinson’s have told us they need answers for these debilitating symptoms that aren’t well treated with current medicines, and the last thing they want is another drug,” said Kent Savage, president & CEO of PhotoPharmics. “So, our goal has been to provide a non-invasive therapy that would significantly improve Parkinson’s symptoms beyond what is currently available.”

“We knew awareness of this new approach was high among the Parkinson’s community, but when we started recruiting, we were overwhelmed by the volume of applications to participate in this pivotal trial,” continued Savage. “After a tremendous amount of work, we are pleased to announce the enrollment of the first 25 patients in the Celeste Light for PD Trial, marking a pivotal moment in our journey to revolutionize PD care.” The non-invasive Celeste phototherapy device has been designated a Breakthrough Treatment by FDA.